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Purpose of the study
To assess the usefulness of monotherapy with lopinavir/
ritonavir (LPV/r) as an option for antiretroviral treat-
ment in clinical practice.
Methods
Seventy-seven subjects (56 men, median age 44.5 years)
with HIV-1 RNA <50 copies/mL for at least 6 months,
were switched to LPV/r as single antiretroviral agent.
Reason for changes were simplification strategy (36.4%)
or toxicity (63.6%) either mitochondrial toxicity (55.8%)
or other (7.8%). Treatment with LPV/r was maintained
for at least 3 months.
Summary of results
The average time from HIV-1 diagnosis to starting
HAART was 54 months. Patients had received a median
of 7 antiretroviral drugs (range 3-14). The previous anti-
retroviral regimen included LPV/r in 55 (71.4%)
patients. After a mean (±SD) follow-up of 25 (±16)
months (median 22 months), viral load remained unde-
tectable in 68 patients (90.7%) (9 of them after reintro-
duction of triple therapy for reasons other than
virological failure), and virological failure was detected
in 9 (11.7%), due to poor adherence in 7 (77.8%). The
median time of undetectable viral load prior to initiating
LPV/r monotherapy was 36 months. The mean CD4+ T
cell count at the time of beginning LPV/r was 518.9
cells/mm3 (range 33−1433) and the end of follow-up
634.5 cells/mm3 (range 99−1547), with an increase of
115.6 cells/mm3. In 8 patients, 13 blips were detected
(viral loads > 50 copies/mL and < 500 copies/mL),
which did not warrant a change in therapy. Differences
between patients with and without virological failure
during LPV/r monotherapy included: older age at HIV-1
diagnosis (40.2 vs 30.7 years, P < 0.049), time of unde-
tectable viral load prior to starting monotherapy (29 vs
45 months, P = 0.05), and CDC category C (77.8% vs
42.6%, P = 0.074). On the other hand, there were no sig-
nificant differences according to sex, risk group, pre-
vious failure to PIs( 9 patients), nadir CD4+ T cell
count, or reasons to change to monotherapy. In the Cox
regression analysis, age was independently associated
with virological failure.
Conclusions
LPV/r monotherapy has been an effective alternative in
clinical practice either as a simplification strategy or in
patients in which toxicity reduces the selection of antire-
troviral drugs. Poor adherence and greater age were
related to a higher rate of therapeutic failure.
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